

MEDICUS

ISSN 1409-6366 UDC 61 Vol · 26 (1) · 2021

Original scientific paper

- 7 THE IMPORTANCE OF HPV VACCINATION IN THE PREVENTION OF CERVICAL CANCER**
Dejan Filipovic¹, Viktor Kamnar², Vladimir Chadikovski³, Kristina Stavridis⁴
- 12 KI67 EXPRESSION IN PAPILLARY THYROID CANCER**
Ilir Vela¹, Sashko Jovev², Goran Kondov⁴, Gordana Petrushevska⁴, Ridvan Bajrami³
- 17 THE ROLE OF RISK OF RENAL FAILURE, INJURY TO THE KIDNEY, FAILURE OF KIDNEY FUNCTION, LOSS OF KIDNEY FUNCTION AND END-STAGE RENAL FAILURE (RIFLE) CLASSIFICATION IN IDENTIFICATION AND PREDICTION SEVERITY OF THE KIDNEY INJURY IN NEWBORNS**
Silvana Naunova Timovska¹, Aspazija Sofijanovska¹, Sonja Bojadzieva¹, Olivera Jordanovska¹, Elizabeta Shuperliska¹
- 22 EXPRESSION OF FILAMIN A GENE CORRELATE WITH THE GRADE, LYMPH NODE INVASION AND STAGE IN COLORECTAL CANCER**
Bujar Osmani¹, Kiril Pakovski², Slavica Josifovska², Zoran Karadzov¹, Sasho Panov²
- 27 RETROSPECTIVE ANALYSIS OF WARFARIN CONTROL USING ROSENDAAL METHOD IN PATIENTS WITH ATRIAL FIBRILLATION**
Ashok Kumar Addepalli¹, Jefry Jose¹, Elstin Ambu Raj¹, Santosha Vooradi¹, Surulivel Rajan M¹, Ranjan Shetty², Rajesh V¹
- 33 SPECTRUM OF HISTOPATHOLOGICAL CHANGES OF THE ENDOMETRIUM IN PATIENTS WITH ABNORMAL UTERINE BLEEDING**
Ana Kocevaska¹, Kristina Skeparovska¹

Profesional paper

- 38 ERYTHEMA MULTIFORME, STEVEN-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS – PEDIATRIC PERSPECTIVES**
Kareva L, Mironska K, Stavrik K, Hasani A
- 46 THE IMPACT OF COGNITIVE FUNCTIONING ON THE QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA**
I.Memedi¹, L.Miloseva²
- 53 PATIENTS WITH CEREBROVASCULAR DISEASE WHO HAVE DEVELOPED DEMENTIA AND COMORBIDITIES DIABETES AND HYPERTENSION IN POLYCLINIC BIT PAZAR – SKOPJE DURING THE YEAR 2017-2020**
Teuta Dalipi¹, Jasmina Mitrevska Velkov¹, Frosina Stojkovska¹, Ivan Barbov¹, Rezeart Dalipi²
- 57 МАКРОЗОМЕН ПЛОД - ИСХОД КАЈ МАЈКА И ПЛОД**
Arta Islami Zulfiu, Bekim Dika, Besa Islami Pocesta, Nurxhan Ajeti, Mirushe Jashari

Review

- 62 ПРЕДИКТИВНА ВАЖНОСТ НА НЕИНВАЗИВНИТЕ МАРКЕРИ НА ФИБРОЗА КАЈ ПАЦИЕНТИ СО АЛКОХОЛНИ ЗАБОЛУВАЊА НА ЦРНИОТ ДРОБ**
Фана Личоска Јосифовиќ, Калина Старделова Гривчевна, Џем Адем, Стефан Пејков, Мери Трајковска

Case report

- 71 CONGENITAL NEPHROLITIASIS WITH COMPLICATIONS, XANTHOGRANULOMATOUS PYELONEPHRITIS AND STENOSIS URETER**
Mogilevska-Gruevska Dragana¹, Kitanovska Katerina², Murtezan Nezafet³, Angelova-Mogilevska Cveta⁴
- 75 DILEMMAS IN THE DIAGNOSIS OF DORSALLY SEQUESTERED DISC IN THE THORACIC SPINE AS A RARE CONDITION**
Gordana Antuleska - Belcheska, Smiljana Bundovska - Kocov, Elizabeta Stojovska - Jovanovska,
- 79 CASE OF OVARIAN ENDOSALPINGIOSIS AS A RARE ENTITY**
Vesna Antovska PhD¹, MD, Shqipe Saracini MD², Eldiar Zulbeari MD³, Blerton Asani⁴
- 82 SEZARY SYNDROM-CASE REPORT**
Telenta Mitrova Julija¹, Ahtarova Biljana²
- 85 ПАРАЛИТИЧЕН СТРАБИЗАМ – АФЕКЦИЈА НА N.ABDUCENS (VI)**
Аншта Божиноска¹, Беким Татеш²
- 89 CANDIDA INTERTRIGO IN A PATIENT ON ICU POSITIVE TO COVID19**
Vesna Trajkova¹, Irena Dimitrovska¹, Hristina Breshkovska², Ivana Tusheva¹, Ruzhdi Rexhepi³
- 92 PLACENTA PREVIA INCRETA: CASE REPORT ЗА УСПЕШЕН МЕНАЏМЕНТ И ОПЕРАТИВЕН ТРЕТМАН НА УРГЕНТНА ОБСТЕТРИЧКА ОПЕРАЦИЈА**
Габриела Бушиноска Иванова¹, Клементина Кузеска², Јорданчо Иванов³, Ррезеарта Елези⁴
- 96 THORACOLUMBAR FRACTURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS (BECHTEREV DISEASE). PRESENTATION OF TREATMENT RISK AND COMPLEXITY THROUGH A COMPLICATION.**
Ilir Hasani MD, PhD, Danica Popovska MD, Rron Elezi MD, Teodora Todorova MD, Arzana Hasani-Jusuifi MD
- 102 КАВЕРНОЗЕН АНГИОМ ВО СЕЛАРНА РЕГИЈА**
Бошковски С.; Тошевска М; Максимоска С.
- 106 СЛУЧАЈ НА ГАСТРИЧЕН МЕТАСТАТСКИ МЕЛАНОМ 2 ГОДИНИ ПО ПОЧЕТНА ДИЈАГНОЗА НА КОЖЕН МЕЛАНОМ**
Арзана Хасани Јусуфи, Мери Трајковска, Урим Исахи, Росалинда Попова Јованова, Викторија Чаловска Иванова, Ѓорѓи Јаневски.



Medical Journal

MEDICUS

ISSN 1409-6366 UDC 61 Vol · 26 (1) · 2021

Revistë Shkencore Nderkombëtare e Shoqatës së Mjekëve Shqiptarë të Maqedonisë
International Journal of Medical Sciences of the Association of the Albanian Doctors from Macedonia

Botues/ Publisher: **SHMSHM / AAMD**

Tel. i Kryeredaktorit / Contact: **+389 (0) 71 240 927**

Zhiro llogaria / drawing account: **200-000031528193**

Numri tatimor / tax number: **4028999123208**

Adresa e Redaksisë-Editorial Board Address: **Mehmed Pashë Deralla nr. 16, Tetovë**
e-mail: **shmshm@live.com**

Kryeredaktori

Prof. Dr. Nevzat Elezi

Editor-in-Chief

Nevzat Elezi, MD, PhD

Redaktorët

Dr. Sci. Besnik Bajrami, Boston, SHBA
Prof. Dr. Atilla Rexhepi, Tetovë, Maqedoni
Prof. Dr. Lul Raka, Prishtinë, Kosovë
Prof. Dr. N. Elezi, Tetovë Maqedoni - Dekan i
Fakultetit të Shkencave Mjekësore - Tetovë
Doc. Dr. Rexhep Selmani, Shkup, Maqedoni

Editors

Besnik Bajrami, MD, PhD, Boston, USA
Atilla Rexhepi, MD, PhD, Tetovo, Macedonia
Lul Raka, MD, PhD, Prishtina, Kosova
N. Elezi, MD, PhD, Tetovo, Macedonia - Dean of
Faculty of Medical Sciences - Tetovo
Rexhep Selmani, MD, PhD, Skopje, Macedonia

Këshilli Redaktues

Nobelisti Prof. Dr. Ferid Murad, Hjuston, SHBA
Prof. Dr. Rifat Latifi, Arizona, SHBA
Prof. Dr. Alex Leventa, Jerusalem, Izrael
Prof. Dr. Sedat Üstündağ, Edirne, Turqi
Prof. asoc. dr. Avdyll Krasniqi, Prishtinë, Kosovë
Prof. dr. sci. Kirk Milhoan, Texas, SHBA
Dr. sci. Minir Hasani, Gjermani
Prof. dr. sci. Alfred Priftanji, Tiranë, Shqipëri
Prof. dr. sci. Naser Ramadani, Prishtinë, Kosovë
Prof. dr. Yovcho Yovchev, Stara Zagora, Bullgari
Doc. Dr. Skender Saiti, Shkup, Maqedoni
Prof. Dr. Milka Zdravkovska, Shkup, Maqedoni
Prof. dr. Gentian Vyshka, Tiranë, Shqipëri
Prim. dr. Gani Karamanaga, Ulqin, Mali Zi
Prof. dr. Ramush Bejiqi, Prishtinë, Kosovë
Dr. Sc. Spec. Meral Rexhepi, Tetovë, Maqedoni
Dr. Sc. Irfan Ahmeti, Shkup, Maqedoni

Editorial Board

Nobel Laureate Ferid Murad, MD, PhD, Houston, USA
Rifat Latifi, MD, PhD, Arizona, USA
Alex Leventa, MD, PhD Jerusalem, Israel
Sedat Ustundağ, Edirne, Turkiye
Avdyll Krasniqi, MD, PhD, Prishtina, Kosova
Kirk Milhoan, MD, PhD, Texas, USA
Minir Hasani, MD, PhD, Germany
Alfred Priftanji, MD, PhD, Tirana, Albania
Naser Ramadani, MD, PhD, Prishtina, Kosova
Yovcho Yovchev, MD, PhD, Stara Zagora, Bulgaria
Skender Saiti, MD, PhD, Skopje, Macedonia
Milka Zdravkovska, MD, PhD, Skopje, Macedonia
Gentian Vyshka, MD, PhD, Tirana, Albania
Gani Karamanaga, MD, Ulcinj, Montenegro
Ramush Bejiqi, MD, PhD, Prishtina, Kosova
Meral Rexhepi, MD, PhD, Tetovo, Macedonia
Irfan Ahmeti, MD, PhD, Skopje, Macedonia

Bordi Këshillëdhënës

Prof. dr. Shpëtim Telegrafi, Nju Jork, SHBA
Prof. dr. Gëzim Boçari, Tiranë, Shqipëri
Prof. dr. Donço Donev, Shkup, Maqedoni
Prof. Dr. Isuf Dedushaj, Prishtinë, Kosovë
Prof. Dr. Ramadan Jashari, Belgjikë
Prof. Dr. Holger Tietzt, Gjermani
Prof. Dr. Vjollca Meka-Sahatçiu
Prof. Dr. Milena Petrovska, Shkup, Maqedoni
Prof. Dr. Sonja Bojaxhieva, Shkup, Maqedoni
Prof. Dr. Kastriot Haxhirexha, Dibër, Maqedoni
Doc. Dr. Naser Durmishi, Shkup, Maqedoni

Sekretariati i redaksisë

Dr. Bekim Ismaili, Maqedoni
Dr. Sead Zeynel, Maqedoni
Dr. Rihan Saiti, Maqedoni

Këshilli Botues

Prim. Dr. Ali Dalipi
Prim. Dr. Ferit Muça
Prim. Dr. Lavdërim Sela
Prim. Dr. Shenasi Jusufi
Dr. Nadi Rustemi
Dr. Bedri Veliu
Dr. Gafur Polisi
Dr. Baki Alili
Dr. Ilber Besimi
Dr. Gazi Mustafa
Dr. Edip Sheji
Dr. Murat Murati
Dr. Dukagjin Osmani
Dr. Bari Abazi
Dr. Fadil Murati
Dr. Fadil Maliqi
Dr. Besa Pocesta-Islami
Dr. Jakup Jakupi
Dr. Muharem Saliu
Dr. Sufjan Belcista-Ferati
Dr. Xhabir Bajrami
Dr. Sc. Majlinda Ademi

Dizajni & Pamja

Aleksandar Kostadinovski

Shtypur në

Shtypshkronjen "Pruf Print", Shkup

Medicus shtypet në tirazh: 600 ekzemplarë
Revista shperndahet falas

Advisory Board

Shpëtim Telegrafi, MD, PhD, New York, USA
Gezim Bocari, MD, PhD, Tirana, Albania
Donco Donev, MD, PhD, Skopje, Macedonia
Isuf Dedushaj, MD, PhD, Prishtina, Kosova
Ramadan Jashari, MD, PhD, Belgium
Holger Tietzt, MD, PhD, Germany
Vjollca Meka-Sahatçiu, MD, PhD
Milena Petrovska, MD, PhD, Skopje, Macedonia
Sonja Bojaxhieva, MD, PhD, Skopje, Macedonia
Kastriot Haxhirexha, MD, PhD, Debar, Macedonia
Naser Durmishi, MD, PhD, Skopje, Macedonia

Editorial Secretariat

Bekim Ismaili, MD, Macedonia
Sead Zeynel, MD, Macedonia
Rihan Saiti, MD, Macedonia

Editorial Council

Ali Dalipi, MD
Ferit Muça, MD
Lavderim Sela, MD
Shenasi Jusufi, MD
Nadi Rustemi, MD
Bedri Veliu, MD
Gafur Polisi, MD
Baki Alili, MD
Ilber Besimi, MD
Gazi Mustafa, MD
Edip Sheji, MD
Murat Murati, MD
Dukagjin Osmani, MD
Bari Abazi, MD
Fadil Murati, MD
Fadil Maliqi, MD
Besa Pocesta-Islami, MD
Jakup Jakupi, MD
Muharem Saliu, MD
Sufjan Belcista-Ferati, MD
Xhabir Bajrami, MD
Majlinda Ademi, MD, PhD

Design & Layout

Aleksandar Kostadinovski

Printed in:

Print House "Pruf Print", Skopje

The Journal Medicus is printed and distributed free of charge with a circulation of 600 copies.

KI67 EXPRESSION IN PAPILLARY THYROID CANCER

Ilir Vela¹, Sashko Jovev², Goran Kondov¹, Gordana Petrushevska⁴, Ridvan Bajrami³

¹Department of Thoracic Surgery, University Clinic for Thoracic and Vascular Surgery, Medical Faculty Skopje, Republic of North Macedonia

²University Clinic for Cardiac Surgery, Medical Faculty Skopje, Republic of North Macedonia

³Department of General Surgery, General Hospital "8 Septemvri" Skopje, Republic of North Macedonia

⁴Institute of Pathology, Medical Faculty Skopje, Republic of North Macedonia

Medicus 2021, Vol. 26 (1): 12-16

ABSTRACT

Background. Papillary thyroid cancer is the most common thyroid cancer and accounts for over 70% of malignant thyroid diseases. In the last few decades the incidence of the papillary thyroid cancer (PTC) has increased worldwide. The aim of the study is to evaluate the Ki67 protein expression in papillary thyroid carcinoma and to correlate with clinicopathological parameters (age, gender, tumor size, vascular invasion, capsule invasion, lymph node metastasis, multifocality).

Materials and methods. The study population consists of 47 patients diagnosed with PTC, and benign thyroid changes. After standard surgical procedure formalin fixed paraffin embedded (FFPE) tissue sections for standard histological and immunohistochemically Ki67 analysis were obtained.

Results. Out of 47 patients, 24 (51.06%) were diagnosed with papillary thyroid cancer (Ki67 expression varies in the range 8.58-5.76%) and 23 (48.94%) were benign changes of the thyroid gland (expression of Ki67 varies in the range 1.61±1.23%). For $Z = 5.49$ and $p < 0.001$ ($p = 0.000$) the cancers had significantly higher Ki67 expression than benign tumors. There was no significant variation in Ki67 expression in papillary thyroid carcinoma in comparison to cervical lymph node metastases and tumor position. These parameters vary with tumor size and multifocality.

Conclusion. Ki67 is an appropriate biomarker used to distinguish papillary carcinoma from benign thyroid lesions. Ki67 expression was associated with tumor size and multifocality. High expression of Ki67 could be an important indicator for assessing the clinical course and prognosis of the disease itself.

Key words. Papillary thyroid cancer, expression and Ki67

BACKGROUND

Thyroid cancers are the most common tumors of the endocrine system and make up about 95% of all tumors of endocrine origin [1]. The development of thyroid cancers, similar to other cancers, uncontrolled cell proliferation must first occur. A number of hormones, growth factors, and steroids regulate the proliferation and function of normal and neoplastic thyroid tissue [2-4].

Cell proliferative activity is an important factor in evaluating the behavior of malignant cells, and Ki67 is one of the most commonly used markers for assessing

the proliferative capacity of malignant cells. Ki67 protein expression is regulated by proteolytic processes, including mechanisms controlled by key regulatory complexes: cyclin B / cyclin-dependent kinases [5]. It is structurally similar to other proteins involved in cell cycle regulation [6]. Ki67 is used in the evaluation of clinical progression and prognosis of malignant tumors. Relevant studies have reported strong protein expression of Ki67 in highly malignant tumors [7]. The prognostic value of Ki67 has been investigated in a number of studies in breast, thyroid, lung, prostate and central nervous system cancers [12-15].

The prevalence of papillary thyroid cancer is almost four times higher in women than in men [8,9] and decreases after menopause [10]. Papillary thyroid cancer is known to have a better prognosis than other malignant tumors of the human body, although about 10% show a worse clinical course than expected. Higher prevalence among women, especially during the reproductive period, is observed in all regions and in all ethnic groups [11].

MATERIALS AND METHODS

This study was performed at the University Clinic for Thoracic and Vascular Surgery at the University "St. Cyril and Methodius" in Skopje, Republic of Macedonia, while immunohistochemically and molecular analyzes of surgical specimens were analyzed at the Institute of Pathology, Faculty of Medicine, Skopje.

The study population consists of 47 patients that underwent thyroidectomy for PTC or subtotal thyroidectomy for benign thyroid disease (thyroid adenomas, goiter). Patients were separated in two groups: group A consists of 24 patients diagnosed with papillary thyroid cancer and group B consists of 23 patients (control group), patients with benign thyroid disease.

Preoperative examinations such as thyroid ultrasound, fine-needle biopsy, and gland scan are performed at the Institute of Nuclear Medicine and Pathological Physiology. Patients with papillary carcinoma are examined by CT scan of the neck with intravenous contrast at the Radiology Clinic, while laboratory tests are performed at the Institute of Clinical Biochemistry.

Surgical technique: Total thyroidectomy is performed under general anesthesia and endotracheal intubation in all cases. An incision of 4 to 6 cm is made in the lower parts of the neck. At that point the subcutaneous tissue and platysma are surgically dissected and we reach to a group of infrahyoid musculature that is dissected. As a result, we reach the thyroid gland, which is completely removed (for subtotal thyroidectomy we remove only the part of thyroid tissue that is pathologically altered) and we are careful to preserve the parathyroid glands and the n.laryngeus recurrens. When we have enlarged lymph nodes we continue with elective cervical dissection.

After gross dissection, formalin fixed paraffin-embedded (FFPE), 4 microns thick tissues sections were stained in standard protocol and used to determine: tumor location, tumor focality, size of the primary tumor, the presence of lymphatic or vascular invasion,

extrathyroidal extension into perithyroidal soft tissue, number of lymph nodes with metastases, margin status and the stage of the disease. The stage of the disease was determined according to the criteria of the Union for International Cancer Control (UICC), 8th edition [19]. The Ki67 immunostaining was performed using DAKO monoclonal antibody (clone Mib1, dilution 1:150), by semi-automated PT Link immunoperoxidase technique. After deparaffinization and rehydration, samples were pretreated with Target Retrieval Solution for 20 minutes at 97°C and then incubated with primary antibody for 20 minutes at 25°C. For antibody detection EnVision FLEX, DAKO visualization system (20 minutes at 25°C) and chromogen -di-amino-benzene-DAB (5 minutes at 25°C) were used. At the end slides were counterstained with hematoxylin.

RESULTS

1. Gender

The study included 47 (100.0%) patients, of which 40 (85.1%) were women and 7 (14.9%) men (Table 1). Out of 40 (85.1%) women, 22 (46.8%) had benign changes in the thyroid gland and 18 (38.3%) were diagnosed with papillary thyroid cancer. Of 7 (14.9%) men, 1 (2.1%) had a benign finding and 6 (12.8%) were diagnosed with papillary thyroid cancer.

There was no significant difference in the cross-tabulation performed between the patient sex and the Fisher's Exact Test diagnostic finding $p > 0.05$ ($p = 0.097$) / Monte Carlo Sig, (2-sided).

Table 1. Gender / Crosstabulation

Benign Carcinoma		Type		Total	
Gender	Female	Count	22	18	40
		%	46,8%	38,3%	85,1%
	Male	Count	1	6	7
		%	2,1%	12,8%	14,9%
Total	Count	23	24	47	
%	48,9%	51,1%	100,0%		

1.1 Gender & Expression

In women, the expression value of Ki67 varies in the range 5.13-5.76% and in men the expression value of Ki67 varies in the range 5.43±3.46%. For $Z = 00.96$ and $p > 0.05$ ($p = 0.34$) men have a slightly higher expression of Ki67 than women (Table 1.1).

Table 1.1 Gender / Difference in expression

Variable	Rank Sum Female	Rank Sum Male	U	Z	p-level	Valid N Female	Valid N Male
Expression	928,00	200,00	108,00	-0,96	0,34	40	7

2. Age of patients

The age of the patients varies in the range 46.30 ± 12.48 years.

Out of a total of 47 (100.00%) patients, 22 (46.81%) were <45 years old (expression of Ki67 varies in the range 6.05-4.92%) and 25 (53.19%) had ≥ 45 years (expression of Ki67 varies in the range 4.40-5.97%). For $Z = -1.63$ and $p > 0.05$ ($p = 0.10$) patients who were <45 years of age had a slightly higher expression of Ki67 than patients who were ≥ 45 years of age (Table 2).

Table 2. Patient age / Ki67 expression

Variable	Rank Sum ≥ 45 yrs	Rank Sum < from 45 yrs	U	Z	p-level	Valid N	Valid N
Expression	523,50	604,50	198,50	-1,63	0,10	25	22

3. Tumor size

Tumor size varies in the range of 1.95-1.13 centimeters. Out of a total of 24 (51.06%) patients, 14 (29.79%) had tumor size <2 cm (expression of Ki67 varies in the range 7.43, 4.50%) and 10 (21.27%) had a tumor size ≥ 2 cm (expression of Ki67 varies in the range of $10.20 \pm 7.10\%$). For $Z = 00.88$ and $p > 0.05$ ($p = 0.38$) patients who had a tumor size ≥ 2 cm had a higher expression of Ki67 than patients who had a tumor size <2 cm (Table 3).

Table 3. Tumor size / Ki67 expression

Variable	Rank Sum < from 2 cm	Rank Sum \geq from 2 cm	U	Z	p-level	Valid N < from 2 cm	Valid N \geq from 2 cm
Expression	160,000	140,000	55,00	-0,88	0,38	14	10

4. Capsule invasion

Out of a total of 24 (51.06%) patients, 13 (27.66%) did not have a capsule invasion (expression of Ki67 varies in the range 7.62-5.77%) and 11 (23.40%) had a capsule invasion (Ki67 expression varies in the range 9.73-5.80%). For $Z = 11.10$ and $p > 0.05$ ($p = 0.27$) patients who had capsule invasion had a slightly higher expression of Ki67 than patients who did not have capsule invasion (Table 4).

Table 4. Capsule Invasion / Expression of Ki67

Variable	Rank Sum No	Rank Sum Yes	U	Z	p-level	Valid N No	Valid N Yes
Expression	143,50	156,50	52,50	-1,10	0,27	13	11

5. Vascular invasion

Out of a total of 24 (51.06%) patients, 23 (48.93%) had vascular invasion of the tumor and in 1 (2.13%) patient vascular invasion was not established.

In patients with vascular invasion of the tumor, the expression of Ki67 varies in the range of 8.52-5.88%.

6. Lymph node metastases

Out of a total of 24 (51.06%) patients, 15 (31.91%) did not have lymph node metastases (expression of Ki67 varies in the range $7.93 \pm 4.28\%$) and 9 (19.15%) had metastases in lymph nodes (expression of Ki67 varies in the range $9.67 \pm 7.81\%$). For $Z = 0.00$ and $p > 0.05$ ($p = 1.00$) There was no significant difference in Ki67 expression between patients who had or did not have lymph node metastases (Table 5).

Table 5. Lymph node metastases / Ki67 expression

Variable	Rank Sum No	Rank Sum Yes	U	Z	p-level	Valid N No	Valid N Yes
Expression	187,50	112,50	67,50	0,00	1,00	15	9

7. Tumor Type & Multifocality

The results shown in Table 6. refer to the performed cross-tabulation between tumor type and multifocal tumors. Of the 23 (48.9%) benign tumors, there was no multifocality. Of the 24 (51.1%) diagnosed papillary thyroid cancer, 18 (38.3%) had no multifocality and 6 (12.8%) had multifocal tumors. In the performed cross-tabulation between tumor type and multifocality for Fisher's Exact Test $p < 0.05$ ($p = 0.022$) / Monte Carlo Sig, (2-sided) there is a significant difference.

Table 6. Tumor type & Multifocality

Yes No	Multifocality		Total	
	Count	%		
Type	Benign	Count 23	0	23
		% 48,9%	0,0%	48,9%
Type	Carcinoma	Count 18	6	24
		% 38,3%	12,8%	51,1%
Total %	Count	41	6	47
	%	87,2%	12,8%	100,0%

8. Tumor type & / Ki67 expression

Out of a total of 47 (100.00%) operated tumors, 24 (51.06%) were diagnosed with papillary thyroid cancer (expression of Ki67 varies in the range 8.58-5.76%) and 23 (48.94%) were benign changes in the thyroid gland (expression of Ki67 varies in the range 1.61±1.23%). For $Z = 5.49$ and $p < 0.001$ ($p = 0.000$) the cancers have significantly higher expression of Ki67 than benign tumors (Table 7).

Table 7. Tumor type & / Ki67 expression

Variable	Rank Sum Carcinoma	Rank Sum Benign	U	Z	p-level	Valid N Carcinoma	Valid N Benign
Expression	834,00	294,00	18,00	5,49	0,000	24	23

DISCUSSION

Thyroid carcinomas mainly develop from follicular cells, only medullary carcinoma develops from parafollicular cells. Papillary carcinomas belong to the group of well-differentiated thyroid cancers. Papillary carcinoma is the most common primary tumor of the thyroid gland and accounts for 70% to 80% of all thyroid cancers. It is more common in women (the ratio of women to men is 2-4: 1) and is less aggressive. However, biological behavior of the tumor is not always as such. Part of papillary thyroid carcinoma can manifest itself in an aggressive nature such as the presence of cervical lymph node metastases, recurrence of the disease itself, distant metastases and even death [16].

Ki67 is a type of protein that acts in DNA binding and is present during cell proliferation. As a marker of cell proliferation, a number of studies are investigating its use in the treatment of tumors. It is mainly located in the cell nucleus and plays an important role in maintaining a stable DNA structure during mitosis. Ki67 has become an important indicator of tumor cell proliferation activity. As Ki67 expression increases, the proliferative activity of tumor cells also increases. Ki67 correlates with the degree of differentiation, tumor invasion, metastasis, and prognosis of many tumors. Patients with high Ki67 expression have a poor prognosis [17]. In this study, the value of Ki67 expression in papillary thyroid cancer relative to benign thyroid changes was statistically significant. Some studies also confirm that Ki67 expression is useful in the differential diagnosis of papillary thyroid cancer [18].

This study showed that Ki67 expression in papillary thyroid cancer is more evident, and correlates with multifocality.

While capsule invasion, tumor size, and patients younger than 45 years had slightly greater expression of Ki67, there was no correlation with sex, cervical lymph node metastases or tumor position. With increasing tumor size and multifocality, the intensity of expression and the positive rate of Ki67 are evidently increased.

We demonstrate that expression of Ki67 is increased in papillary thyroid cancer. Expression of Ki67 in papillary carcinoma has been associated with tumor size and multifocality.

CONCLUSION

Ki67 is an appropriate biomarker used to distinguish papillary carcinoma from benign thyroid lesions. Ki67 expression was associated with tumor size and multifocality. High expression of Ki67 could be an important indicator for assessing the clinical course and prognosis of the disease itself.

REFERENCES

- Antonio De la Vieja, Orsolya Dohan, orlie Levy and 1. Nancy Carrasco. Molecular Analysis of the Sodium/Iodide Symporter: Impact on Thyroid and Extrathyroid Pathophysiology. *Physiological Reviews*. 2000;80:1083-1105
- Bonacci R, Pinchera A, Fierabracci P, Gigliotti A, Grasso L and Giani C: Relevance of estrogen and progesterone receptors enzyme immunoassay in malignant, benign and surrounding normal thyroid tissue. *J Endocrinol Invest* 19: 159-164, 1996.
- Metaye T, Millet C, Kraimps JL, Aubouin B, Barbier J and Begon F: Estrogen receptors and cathepsin D in human thyroid tissue. *Cancer* 72: 1991-1996, 1993.
- Nagy N, Camby I, Decaestecker C, Chaboteaux C, Gras T, Darro F, Rocmans P, Kiss R and Salmon I: The influence of L-triiodothyronine, L-thyroxine, estradiol-17beta, the luteinizinghormone-releasing hormone, the epidermal growth factor and gastrin on cell proliferation in organ cultures of 35 benign and 13 malignant human thyroid tumors. *J Cancer Res ClinOncol* 125: 361-368, 1999.
- Rahmanzadeh R, Hüttmann G, Gerdes J and Sholzen T: Chromophore-assisted light inactivation of pKi67 leads to inhibition of ribosomal RNA synthesis. *Cell Prolif*. 40:422-430. 2007. View Article : Google Scholar : Pub-Med/NCBI
- Choudhury M, Singh S, Agarwal S, et al (2011). Diagnos-

- tic utility of Ki67 and p53 immunostaining on solitary thyroid nodule--a cytohistological and radionuclide scintigraphic study. *Indian J PatholMicrobiol*, 54, 472-57.
- Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M and Gustafsson JA: Update on estrogen signaling. *FEBS Lett* 546: 17-24, 2003
7. Chen Y, Klingen TA, Wik E, et al (2014). Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study. *DiagnPathol*, 9, 230
 8. Correa P, Chen VW: Endocrine gland cancer. *Cancer* 1995;75:338-352.
 9. Rosenthal DS: Changing trends. *CA Cancer J Clin* 1998;48:3-4
 10. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M: Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. *J ClinEndocrinolMetab* 2001;86:1072-1077.
 11. Preston-Martin S, Bernstein L, Pike MC, Maldonado AA, Henderson BE: Thyroid cancer among young women related to prior thyroid disease and pregnancy history. *Br J Cancer* 1987;55:191-195.
 12. Ishihara M, Mukai H, Nagai S, et al: Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival. *Oncology*. 84:135-140. 2013. View Article : Google Scholar
 13. Sorbye SW, Kilvaer TK, Valkov A, et al: Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. *PLoS One*. 7:e470682012.
 14. Sorbye SW, Kilvaer TK, Valkov A, et al: Prognostic impact of CD57, CD68, M-CSF, CSF- 1R, Ki67 and TGF-beta in soft tissue sarcomas. *BMC ClinPathol*. 12:72012. View Article : Google Scholar : PubMed/NCBI
 15. Ciancio N, Galasso MG, Campisi R, et al: Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. *MultidiscipRespir Med*. 7:292012. View Article : Google Scholar : PubMed/NCBI
 16. Zafon C, Baena JA, Castellvi J, et al (2010). Differences in the form of presentation between papillary microcarcinoma and papillary carcinomas of larger size. *J Thyroid Res*, 2011, 639156.
 17. Klintman M, Bendahl PO, Graban D, et al (2010). The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. *Mod Pathol*, 23, 251-9
 18. Aiad HA, Bashandy MA, Abdou AG, et al (2013). Significance of AgNORs and ki67 proliferative markers in differential diagnosis of thyroid lesions. *PtholOncol Res*, 19, 167-75.
 19. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. *AJCC Cancer Staging Manual*. 8th edn. New York, NY: Springer (2017).